Dr. Braunwald, Professor at Harvard Medical School, is a world-renowned expert in the field of cardiovascular medicine and is believed to be the most frequently cited author in the field of cardiology, with more than 1000 publications in peer-reviewed journals. His landmark research includes the identification of hypertrophic cardiomyopathy as a clinical entity. As Founder and Chairman of the TIMI Study Group, one of their many achievements was the PROVE-IT TIMI 22 Trial, which demonstrated the benefit of intensive reduction of LDL cholesterol by statin therapy. Dr. Braunwald will be joining a panel at the 12th Annual CMHC that includes Drs. Christie Ballantyne, Paul Ridker, and Marc Sabatine to discuss the clinical trials FOURIER, REVEAL, and CANTOS.
Boston, July 22, 2016––The Cardiometabolic Health Congress has announced 5 Keynote presentations have been scheduled for the 11th Annual CMHC, taking place October 5-8, 2016, at the Sheraton in Boston, MA. The 3 ½-day event has become the largest US-based, multidisciplinary conference focused solely on the prevention, diagnosis, and management of cardiovascular and metabolic diseases.
The increased number of Keynotes for this year’s Annual Meeting will address the growing areas of cardiometabolic disease management and are as follows: Read more